Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: May 15, 2025

RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) initiated with topline interim data expected in the first half of 2026